MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

0.36 -7.69

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.35

Max

0.4

Belangrijke statistieken

By Trading Economics

Inkomsten

-982K

-10M

Verkoop

54K

130K

Winstmarge

-7,873.077

Werknemers

23

EBITDA

-1.8M

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+607.5% upside

Dividenden

By Dow Jones

Volgende Winsten

12 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.7M

27M

Vorige openingsprijs

8.05

Vorige sluitingsprijs

0.36

Nieuwssentiment

By Acuity

50%

50%

148 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jul 2025, 22:07 UTC

Belangrijke Marktbewegers

Trade Desk Rises on S&P 500 Inclusion

14 jul 2025, 17:06 UTC

Belangrijke Marktbewegers

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 jul 2025, 16:47 UTC

Acquisities, Fusies, Overnames

NatWest to Sell Stake in Permanent TSB

14 jul 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

14 jul 2025, 23:38 UTC

Marktinformatie

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 jul 2025, 23:37 UTC

Marktinformatie

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 jul 2025, 23:29 UTC

Marktinformatie

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 jul 2025, 23:29 UTC

Marktinformatie

Global Energy Roundup: Market Talk

14 jul 2025, 23:02 UTC

Winsten

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 jul 2025, 23:02 UTC

Winsten

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 jul 2025, 23:02 UTC

Winsten

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 jul 2025, 23:01 UTC

Winsten

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 jul 2025, 23:01 UTC

Winsten

China Vanke Expects 1H Loss to Widen >000002.SZ

14 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

14 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jul 2025, 20:07 UTC

Marktinformatie

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 jul 2025, 20:05 UTC

Marktinformatie

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 jul 2025, 19:11 UTC

Marktinformatie

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 jul 2025, 19:09 UTC

Marktinformatie

Gold Breaks a 3-Day Win Streak -- Market Talk

14 jul 2025, 18:59 UTC

Marktinformatie

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 jul 2025, 18:30 UTC

Acquisities, Fusies, Overnames

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 jul 2025, 18:25 UTC

Marktinformatie

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 jul 2025, 18:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 jul 2025, 16:59 UTC

Marktinformatie

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 jul 2025, 16:53 UTC

Populaire aandelen

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 jul 2025, 16:27 UTC

Marktinformatie

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

14 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

14 jul 2025, 16:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

607.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.83 USD  607.5%

Hoogste 4 USD

Laagste 1.5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

148 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.